Introduction
Treatment concepts and survival of multiple myeloma (MM) patients have substantially changed due to our better understanding of the disease, novel risk-adapted therapies and improved supportive care measures [1] [2] [3] . MM typically affects elderly patients whose prognosis varies widely and remains more unfavorable than in younger patients. This is shown to be related to a higher frequency of treatment discontinuation and non-hematological adverse events [3] [4] [5] [6] [7] [8] . Moreover, elderly and frail patients are less frequently included in clinical trials and may receive fewer novel agents [2] [3] [4] [7] [8] [9] [10] . This typically occurs because multimorbidity and interaction of various medications can complicate patients' treatment, limit their physical condition and impair survival 7, 8, 10 .
However, the global population is rapidly aging and the increasing number of elderly patients demands reliable tools to assess their vulnerability as expressed in chronic conditions and limitations in daily activities. Novel risk scores can either rely on MM tumor burden, as postulated with the combined use of the International Staging System (ISS), LDH and high-risk cytogenetics 5, 11 , and/or patients' functional condition, which is assessed worldwide [12] [13] [14] [15] [16] . A functional or geriatric assessment (GA) offers the possible advantage of guiding therapeutic decisions and may prove essential when accounting for treatment compatibility, drug-induced side effects, and mortality 2, 14, 17, 18 . This has been acknowledged as relevant, apart from those risks generated through the myeloma itself and competent clinical judgement. 4 . Indeed, prospective randomized studies constitute a good basis for the development of prognostic scores, since they meet all requirements postulated to be important 2, [6] [7] [8] .
However they bear the nominal challenge that patients therein are selected due to strict inclusion criteria. Therefore, internal and external validation of postulated prognostic scores in unselected patient cohorts is necessary 7, 8, 10, 19 .
Since the IMWG score was tested, but not validated, the authors encouraged others to substantiate their findings 4, 6 . In particular, "real world" patients were urged to be assessed, since the IMWG data was based on clinical trial patients that were stringently treated within trial protocols, where the frailest patients are excluded 6 . Thus, it was of relevance to assess the external validity of the IMWG score in order to obtain confirmation in "real-world" patients from population-based registries and prospective analyses 6 . Splitting the IMWG cohort by the investigators into a test and validation cohort would have resulted in an internal validation, again bearing the limitation to be solely based on clinical trial participants 19 .
We here prospectively and carefully assessed the IMWG score's impact on clinical outcome and are the first who have thoroughly validated the IMWG baseline GA in a well-characterized external cohort.
Since our prior analyses demonstrated that multivariate risk factors in MM patients include impaired renal-, lung-function and Karnofsky performance status (KPS) 2, 7, 8, 10, 20 , and that with a revised Myeloma Comorbidity Index (R-MCI), the inclusion of frailty, age and cytogenetics improves its prediction of fit, intermediate fit and frail patients 21 , we included the R-MCI, CCI, HCT-CI and KF in this analysis. Our intention was validation, not improvement of the IMWG score, diligently performed here.
Methods
Patient population and study design. In analogy to the IMWG analysis 4 , we performed a baseline GA in 125 consecutive patients with MM at the time of initial diagnosis and first presentation at our centre. Patients received standard antimyeloma treatment according to the institutional MM pathway and current recommendations 2, 22 Diversity of different induction regimens in the IMWG cohort vs. ours were seven vs. six, respectively.
As treatment differed both in the IMWG and our cohort, both analyses adjusted their univariate and multivariate models for known prognostic factors (ISS, cytogenetics and therapy).
The analysis was carried out according to the guidelines of the Declaration of Helsinki and Good Clinical Practice. All patients gave their written informed consent for institutional-initiated research studies and analyses of clinical outcome studies conforming to the institutional review board guidelines. The study was registered at www.clinicaltrials.gov (DRKS-00003868).
The primary objectives of this analysis were to recapitulate the IMWG score in our MM cohort, to assess additional GA tools to predict fit vs. frail patients and how these geriatric parameters predict overall survival (OS). The secondary objectives included the impact of the IMWG score as compared to the R-MCI, CCI, HCT-CI and KF, and to assess their value for OS and progression free survival (PFS).
Assessment.
The GA consisted of 6 tools: the Katz ADL, Lawton IADL, CCI, HCT-CI, KF and R-MCI as described 4, 9, 18, 21, 22 . The comorbidities assessed in the R-MCI are depicted in Supplementary Table   1 , and the CCI, HCT-CI, KF and R-MCI in Supplementary The Fried definition was utilized for frailty: this takes into account the added presence of weakness, poor endurance, low physical activity and slow gait speed 27, 28 . Patient characteristics included age, ISS and treatment (Table 1) .
Statistical analysis. Data were analyzed using SAS 9.2 (SAS Institute Inc., USA). OS was calculated from the date of first presentation at our center until the date of death from any cause, while PFS was calculated from the date of first presentation until the date of progression, relapse or death from any cause. Observations, where the event of interest did not occur, were censored at the time last seen alive/without documented event, or at the latest on June 1st, 2015. OS and PFS rates were estimated using the Kaplan-Meier method and compared using the log-rank-test.
The IMWG score was assessed and compared to the R-MCI, HCT-CI, CCI and KF, evaluating the prognostic role on OS in our cohort with Cox regression models ( Table 2) . Results were presented as estimated hazard ratios (HR) with two-sided 95% confidence intervals (CI) and corresponding p-values (Table 2) . Cox regression models obtained and displayed in the analysis of the IMWG data were repeated using our data (Table 2-4) in order to compare the IMWG score and R-MCI, as well as other internationally renowned, but MM-unspecific comorbidity scores, such as the CCI, HCT-CI and KF (Table 3+4 ).
Multivariate risks, on which the IMWG score is based 4 , were used to score fit, intermediate-fit and frail patients ( Table 2 ). This IMWG score was also applied in order to compare fit vs. frail patients defined by the use of the R-MCI, CCI, HCT-CI and KF (Table 3) , and via univariate and multivariate models evaluating the prognostic value of the scores, alone and adjusted for known prognostic factors (ISS, cytogenetics, therapy; Table 4 ): 125 patients with 28 OS events (deaths) and 64 PFS events (death or disease progression) were included in the analyses. Our main results relied on univariate Cox models, namely the presentation of OS and PFS comparisons according to patients' fitness scores (Table 4) , and on multivariate analyses to adjust for 2-3 additional known prognostic factors (Table 4) .
Results
Patient characteristics. The analysis included 125 consecutive, prospectively assessed MM patients.
The median follow-up was 28 months (interquartile range [IQR] 22-33). The median age was 63 years, 26% of patients were 66-74 years and 15% older than 75 years (Table 1) , which is typical for tertiary centres 7, 8, 10, 21, 22, 29 . This was in contrast to the IMWG cohort 4 , where 46% of patients were older than 75 years (Table 1) , albeit various other patient characteristics were comparable, e.g. renal function in both showed median creatinine of 1mg/dl, the ECOG performance status (PS) 0-1 was similarly distributed with 72% and 76%, patients had mostly ISS II/III stages in 72% and 73%, respectively, and the frequencies of unfavorable, favorable and missing chromosomal aberrations appeared similar.
Moreover, the median IADL in both cohorts was uncompromised at 8 ( Table 1) .
Since the IMWG cohort consisted exclusively of clinical trial patients 4 and ours of consecutive "real world" patients, there were some differences: the number of patients with substantial renal impairment (creatinine >2mg/dl) was 15% in our cohort (IMWG cohort: 5%), our patients showed an ECOG PS of 2-3 in 28% (IMWG: 21%), ISS III frequencies were higher at 38% (IMWG 31%), and unfavorable cytogenetics in 32% of our patients increased as compared to 24% in the IMWG cohort. Unfavorable, favorable and missing cytogenetics in the IMWG cohort were 24%, 38% and 17% vs. 32%, 51% and 17% in ours, respectively, suggesting with the IMWG cytogenetic data in 79% of patients that another 21% were missing (17+21%=38%). Supporting the characteristics of our real world patients vs. the IMWG cohort, our median ADL was lower with 4 vs. 6, and the CCI higher with 2 vs. 0, respectively (Table 1 ). In agreement with these findings, the median HCT-CI, KF and R-MCI in our patients -not objectives of the IMWG analysis -were 2, 1 and 5, respectively, and thus reflected a typical, moderately impaired patient cohort 2, 7, 8, 10, 22, 29 .
Identification of prognostic variables in the Cox regression model. . In our patients, the IADL and CCI revealed higher HR and reached significance for the CCI, which was likely related to our median CCI of 2 rather than 0 in the IMWG trial cohort. Therefore, more CCI-relevant comorbidities were present in our vs. within the IMWG clientele 4 ( Table   3+4 ). In the multivariate analysis we also confirmed that, when adjusted for staging and treatment administered, frailty profiles and comorbidity scores were associated with shorter OS (Table 4) .
By applying the IMWG score, the 3-year PFS in our cohort was 43% for fit, 25% for intermediate-fit (HR Table 3+4 ). PFS for fit patients was comparable to the IMWG data, albeit lower for intermediate-fit and frail patients, which was likely related to more patients with comorbidities, higher CCI and lower ADL in our cohort (Table 1+3) .
Using the 4 other comorbidity scores, namely R-MCI, CCI, HCT-CI and KF, also allowed division of fit and frail patients based on previously proposed cut-offs, with substantially different OS and PFS (Table   3 ). Of note, the proportion of patients via elevated HCT-CI
substantially, with 38%, 51%, 65% and 78%, respectively (Table 3) . Nevertheless, all 4 scores revealed PFS and OS group differences between fit and frail patients, the most pronounced being observed with the use of the IMWG, CCI and R-MCI ( Figures 1+2 A-C) .
Univariate and multivariate analysis of the impact of frailty on OS and PFS for the University
Clinic Freiburg (UKF) and IMWG cohorts. In Table 3 , 3-year OS and PFS rates are presented with accompanying 95% CI. These comparisons refer to one single time point, where CIs are large due to smaller observation numbers at the end of the observation period. With Table 3 , we intended to provide additional descriptive information to Figures 1+2 and to provide comparability to 3-year OS and PFS rates reported by the IMWG 4 . The proper way to compare groups with respect to OS and PFS over the complete observation period is via Cox models as presented in Table 4 . HRs via multivariate analysis were associated with shorter OS and PFS using the IMWG score, as well as when R-MCI, CCI, HCT-CI and KF were applied. These frailty scores reached significance for OS with the use of the IMWG score for frail vs. both fit and intermediate-fit patients, although the two fittest patient groups clustered together. Similarly, significant OS differences between fit and frail patients were notable with the use of both the R-MCI and CCI. For PFS, the IMWG score showed differences for frail patients vs.
the two fitter patient groups, however this difference did not reach significance in our cohort. Significant PFS differences via CCI (<2 vs. These frailty scores continued to be associated with shorter OS and PFS when adjusted for staging and treatment administered, again with the most pronounced group differences being those between frail vs. fitter patients when these were determined using the IMWG score, CCI and R-MCI (Table 4) .
Discussion
MM management strategies continue to evolve, and in the past few decades survival has improved
significantly, yet the overall prognosis depends on a variety of disease-and host-related risks. 21 .
Other studies have confirmed the relevance of assessing frailty, quality of life and physical activity 18, 32, 34, 35 . The assessment of organ function, such as renal and lung impairment, has shown to influence survival rates, treatment toxicity and early death 8, 16, 36 . Moreover, tumor genetics have been reported to relevantly influence the clinical heterogeneity of MM 1, 11, 14, 25, 37, 38 . Although cytogenetics are important for risk appraisal, we and others have demonstrated that physical condition and organ function are likewise crucial 7, 8, 10, 18 .
We here assessed the IMWG score 4 in an independent external validation cohort. Patient characteristics were comparable, with a median creatinine of 1mg/dl, an ECOG PS of 0-1 which was similarly distributed, primarily ISS II/III stages, and uncompromised median IADL of 8. However, there were differences: more of our patients had unfavorable cytogenetics, lower ADL and higher CCI, which is in agreement with the IMWG cohort consisting of clinical trial patients only with tight inclusion criteria.
Importantly, we confirmed that an age <80 years may not substantially increase the risk for MM patients, demonstrating that suitable comorbidity tools and a precisely performed GA are helpful. (Table 4) . Both the CCI and R-MCI, divided into fit vs. frail, showed substantially increased HRs for OS and PFS, whereas less pronounced differences for fit vs.
frail patients were obvious with the use of both KF and HCT-CI. Therefore, our detailed comparison of both the crude and adjusted IMWG score with others, suggested some to be of particular value in MM, such as the IMWG score, CCI and R-MCI, whereas others, such as the KF and HCT-CI were of lesser significance. The CCI in particular has been tested in several clinical settings and showed its usefulness 9, 12, 18, 34 . However, scoring of the CCI has been modified 2,4,7-10,18,39 since it is not specific for MM. Why the IMWG has chosen the CCI to complement their IMWG score is therefore a possible choice, albeit the CCI has been validated in diabetes and its value has also been questioned, the more as the median CCI in the IMWG cohort was extremely low with 0. Our results, that all comorbidity tools: This is the first validation study that externally confirmed the IMWG score and other relevant comorbidity tools in real life patients, yet our cohort was smaller, nevertheless provides useful information for a validation analysis. A common procedure is to divide a sample number into 2/3 for score construction and 1/3 for internal validation. In the IMWG analysis 4 , smaller subgroup analyses were performed, which resulted in reduced sample sizes as well. Therefore, we consider our data valuable, supporting the usefulness of the IMWG score (and others) when applied to different populations. Albeit our patients were typical for a university centre, they were younger than the IMWG cohort 4 . We have previously shown that stage and age migration may occur 29 and that older patients are increasingly seen in university centres: in a previous analysis of 816 MM patients, 3-fold increases for >70-year old patients were observed 29 . In this analysis we confirmed that HR for 60-70 and >70-year old MM patients increase from 1.72 to 3.46, respectively 29 . The reason, why the IMWG cohort did not see an age risk in 76-80-year old patients was most likely because a) age is lesser a risk factor than initially presumed -making simple comorbidity assessments as performed with experience as in our centers the more important, and b) because the IMWG cohort included only trial patients that are much fitter and age is less relevant in those that fulfill all eligibility criteria. Another criticism might be that antimyeloma treatment differed from those used in the IMWG study 4 . Since easily assessable risk scores are important to apply independent of treatment, and previous analyses have shown that heterogeneous therapies are not surrogates for comorbidity risks, we consider our analysis to be of equal importance to prior GA-analyses, including the IMWG. This is even more so, since we validated and complemented their findings, and all risk scores were assessed as crude and adjusted scores (Table 4) 4 .
Strengths of this analysis were the accurate and prospective assessment of patients´ physical condition with no restriction of validity and information loss based on multicentre data entries 6 .
Moreover, our cohort reflected typical day to day patients, since ADL and CCI were affected compared to the IMWG cohort, whereas in both the IADL was uncompromised with a median of 8. This suggests this daily activity score to be of lesser importance and questions the necessity to use both ADL and IADL in a combined risk score. Our thoroughly performed validation of the IMWG score and others, including the R-MCI, was performed within a structured prospective GA and by an experienced group who has been doing these assessments for years 2, 7, 10, 20, 21 . Moreover, we applied all current state-ofthe-art statistics with our renowned statistical team with the important aim to validate easy to assess risk scores that thrive to improve MM care 40 .
Currently, the IMWG score consists of 1. age (3 age groups), 2. ADL (6 self-care tasks), 3. IADL (8 house-hold tasks) and 4. CCI (18 factors and maximum points of 33, plus 1 per decade from an age of 50). As a sum risk assessment, thus constitute of 3+10+8+18=39 risks, instead of 6 within the R-MCI.
Thus, within the IMWG score (including age=1. and CCI=4.), age is scored twice; suggesting with the direct comparison of both IMWG score and R-MCI that the former is more challenging than the latter.
This can be verified, if the R-MCI is calculated via webpage in 1-2 minutes (www.myelomacomorbidityindex.org). Nevertheless, our intention was pure validation of the IMWG score, which we performed fastidiously. As with the IMWG score, treatment was not modified according to this score. A next step includes prospective randomized clinical studies to design therapeutic approaches with the help of a GA algorithm 2, 14, 20, 41, 42 . We conclude that both IMWG score and R-MCI are useful instruments in older myeloma patients for identifying those with geriatric risks.
The publication of our validation analysis should attract cancer experts' attention and help in the eager care of MM patients, aims that all of us are enthusiastically thriving at daily. (A) PFS in our patients divided into fit, intermediate-fit and frail patients showed group differences between both fitter patient groups and frail patients using the IMWG score.
(B) PFS according to the R-MCI revealed better group distinctions between fit, intermediate-fit and frail patents.
(C-E) PFS according to CCI risk groups showed again significant difference, whereas these were undetectable with use of both HCT-CI (D) and Kaplan Feinstein (E). Abbreviations: CCI, Charlson Comorbidity Index; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index; KF, Kaplan Feinstein, a adjusted KF: without malignancies; KPS, Karnofsky Performance Status; pts, patients; y, years Scoring rules: a) R-MCI/MCI/HCT-CI/CCI: Addition of present comorbidities, sum score; b) adjusted KF: the number of points range from 0 to 3; in case of coexistence of several comorbidities the most severe comorbidity is considered; if ≥2 comorbidities exist in one patient with a grading of 2 points each, the total number of points is 3
